These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 11099325)

  • 21. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
    Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
    Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.
    Jones SF; Greco FA; Hainsworth JD; Patton JW; Barton JH; Willcutt NT; Baker MN; McGuirt PV; Levin J; Burris HA
    Oncologist; 2002; 7(5):444-50. PubMed ID: 12401907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
    Rivera E; Chang JC; Semiglazov V; Burdaeva O; Kirby MG; Spector T
    Clin Breast Cancer; 2014 Feb; 14(1):26-30. PubMed ID: 24183612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
    Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.
    Saif MW; Wilson RH; Harold N; Keith B; Dougherty DS; Grem JL
    Anticancer Drugs; 2001 Jul; 12(6):525-31. PubMed ID: 11459999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.
    Saleem A; Yap J; Osman S; Brady F; Suttle B; Lucas SV; Jones T; Price PM; Aboagye EO
    Lancet; 2000 Jun; 355(9221):2125-31. PubMed ID: 10902627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
    Rivera E; Valero V; Cristofanilli M; Frye DK; Booser DJ; Rosales MM; Hortobagyi GN
    Cancer; 2002 May; 94(9):2321-6. PubMed ID: 12015755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
    Czito BG; Hong TJ; Cohen DP; Petros WP; Tyler DS; Pappas TN; Yu D; Lee CG; Lockhart AC; Morse MA; Fernando N; Hurwitz HI
    Cancer Invest; 2006 Feb; 24(1):9-17. PubMed ID: 16466986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
    Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
    Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
    Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
    Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
    J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
    Ahmed FY; Johnston SJ; Cassidy J; O'Kelly T; Binnie N; Murray GI; van Gennip AH; Abeling NG; Knight S; McLeod HL
    J Clin Oncol; 1999 Aug; 17(8):2439-45. PubMed ID: 10561307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
    Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
    Shepard DR; Mani S; Kastrissios H; Learned-Coughlin S; Smith D; Ertel P; Magnum S; Janisch L; Fleming GF; Schilsky RL; Ratain MJ
    Cancer Chemother Pharmacol; 2002 May; 49(5):398-402. PubMed ID: 11976834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
    Mani S; Hochster H; Beck T; Chevlen EM; O'Rourke MA; Weaver CH; Bell WN; White R; McGuirt C; Levin J; Hohneker J; Schilsky RL; Lokich J
    J Clin Oncol; 2000 Aug; 18(15):2894-901. PubMed ID: 10920138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
    Benson AB
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
    Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
    Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.